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Abstract
Papillary thyroid cancer has increased in incidence dramatically over the past three decades
making it the fastest rising cancer diagnosis in the world. The prognosis of this disease remains excellent
despite this dramatic rise which has called into question the risk of overdiagnosis and overtreatment of
this disease. The American Thyroid Associated (ATA) currently recommends surgical treatment for all
confirmed malignant thyroid nodules over 1 cm in diameter. However, some research suggests that
tumors under 1 cm have a greater prevalence of lymph node metastases while other research suggests
that observation is an appropriate option for tumors greater than 1 cm without other unfavorable
features. In order to provide the best management for this disease, clinicians should be monitoring
emerging studies on this topic while researchers need to explore the outcomes from the various
treatment modalities. In the meantime, treatment for papillary thyroid cancer should be evaluated and
treated on an individualized basis.

Introduction
When patients learn that they have cancer, they experience heightened anxiety and expect to
be comforted with a clear treatment plan outlined by their clinicians. In the case of papillary thyroid
cancer, the guidelines are changing and providers and patients alike are confused about how to
proceed. This lack of consensus is particularly relevant because a significant increase in the incidence of
papillary thyroid cancer has occurred in the last three decades, making it the fastest rising cancer in the
US, the 6th leading cancer diagnosis in the world and the most common endocrine malignancy.1
Nonetheless, the prognosis of papillary thyroid cancer has remained extremely favorable and its
mortality rate has remained unchanged despite the significant increased incidence rate.2 The reason for
the increased incidence is not fully understood at this time; however, the hypothesis most recognized is
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that advancements and increasing availability of imaging techniques such as neck ultrasound, have
improved the ability to diagnose small thyroid nodules, thus increasing the frequency of diagnosis.
This increased frequency of diagnosis has created controversy among providers and researchers
regarding the treatment of this cancer especially because of concerns about potential overtreatment of
cancer that has such an excellent prognosis if left untreated. Currently, many sources provide
suggestions on how to proceed with treatment but few well-funded, peer-reviewed controlled trials are
available to help providers make evidence-based decisions.3 The standard of treatment for papillary
thyroid cancer as defined by the American Thyroid Association is to achieve disease-free status through
surgical treatment of malignant thyroid nodules > 1 cm followed by radioactive iodine ablation and
lifelong thyroid hormone replacement.3 Additionally, to eliminate risk for overtreatment, the
recommendations state that thyroid nodules found on imaging should not be biopsied until they are > 1
cm. Despite these guidelines, the lack of consensus about treatment options in clinical practice causes
confusion for providers and their patients. Furthermore, active surveillance of papillary thyroid cancer
given its indolent nature and excellent prognosis has become a more popular option in recent years. The
different therapeutic options available to patients with papillary thyroid cancer will be explored, with
the focus on whether observation or standard surgical treatment provides the best overall outcome for
patients.

Discussion
Despite the increased incidence of thyroid cancer over the past several decades, mortality rates
have not changed and survival rates have remained stable at over 98% at five-year follow up.4 This
excellent prognosis challenges current recommendations of surgical excision of thyroid nodules. As a
result, researchers have suggested the possibility of observation instead of surgery in cases of papillary
thyroid cancer. One such study from Kuma Hospital in Japan planned to prove this hypothesis and
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conducted an observational trial for >700 patients diagnosed with papillary thyroid cancer from the
years of 1993 to 2001. In this study, patients with papillary thyroid cancer but without unfavorable
characteristics (such as tumors located adjacent to the trachea, tumors invading the recurrent laryngeal
nerve, or lymph nodes highly suspicious of metastasis) were given the option to choose observation or
the standard surgical treatment. The observation group was followed annually; tumor size as well as
evaluation for lymph node metastases were recorded each year. At one year follow up, 70% of patients
did not have any change in tumor size. Furthermore, at five-year follow up, 72.3% of the previously
unchanged group did not have any change.5 These findings were significant in that they provided strong
evidence supporting the hypothesis that observation of thyroid cancer is a valid therapeutic approach.
However, in this same study, it was determined that microcarcinomas, which are defined as less than 1
cm, were found to have a higher rate of lymph node metastases than the larger tumors. This is
important because it challenges the original guidelines from the American Thyroid Association that
recommend observation rather than biopsy of thyroid nodules under 1 cm. The strength of this study
comes from its large sample size; however, limitations included the retrospective and observational
study design and the duration of follow up being limited to 5 years.
Another study published in 2017 examined whether immediate surgery versus delayed surgery
and observation had any effect on clinical outcomes. The study separated patients into three groups,
one with immediate surgery, one with surgery between 6-12 months of diagnosis, and surgery 12
months after diagnosis. No significant differences in thyroid cancer, either recurrence or persistent
disease were found among the patients in the three groups. This evidence reinforced the idea that a
period of observation of thyroid cancer could be offered to patients without adversely affecting their
long-term prognosis.6 Like the prior study, the strength of this research comes from its large sample size
of 2863 patients. However, the patients are from a single hospital which may have led to bias in
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determining which treatment option to choose. Furthermore, it is a retrospective observational study,
limiting its quality of evidence.
The slow growing nature of thyroid cancer along with its behavior of remaining latent for many
years without harmful effects has also led researchers to evaluate the potential complications of
traditional surgical treatment of thyroid cancer. The risks of thyroid surgery include transient
hypoparathyroidism, permanent hypoparathyroidism, potential laryngeal nerve damage, and
permanent vocal cord paralysis; nonetheless, the risks of long term damage are relatively low at 0.2%
for permanent vocal cord paralysis and 1.6% for permanent hypoparathyroidism.7 One of the most
significant negative outcomes of thyroid surgery is a decrease in the quality of life due to the need for
lifelong hormone replacement with levothyroxine. The potential adverse effects reported with
levothyroxine treatment can include thyrotoxic symptoms that lead to reduced exercise tolerance,
anxiety, and cardiovascular effects like increased resting heart rate, tachyarrhythmias, and atrial
fibrillation.8 Lifelong levothyroxine treatment with TSH-suppressing doses necessary for preventing
papillary thyroid cancer recurrence can also lead to decreased bone mineral density with consequent
increased risk of osteoporosis and fragility fractures.8 These latter effects are more likely to occur when
TSH levels are suppressed to 0-0.3 mU/L which is the recommendation for TSH-dependent tumors.
Furthermore, appropriate TSH levels can be difficult to manage and require close follow up which
include several appointments a year for these patients and multiple trips to the laboratory for
monitoring, all of which are expensive and can affect the quality of life.
Other risks from traditional therapy include toxicities and complications due to radioactive
iodine (RAI) treatment for remnant thyroid cancer ablation. The use of RAI has been routine after total
thyroidectomy given the high percentage of lymph node metastases with papillary thyroid cancer but
few studies have outlined the risks of RAI. A study in 2015 examined these risks and found that the use
of RAI increased from 4% in 1972 to 40% in 2008. Patients who received RAI had significantly elevated
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risk of developing secondary malignancy later in life at a rate of 1 in every 227 individuals compared to
individuals who did not receive RAI.9 The most prevalent secondary malignancies include leukemia and
salivary gland cancer. Other studies revealed chronic toxicities from RAI including sialadenitis,
oligospermia, and ovarian failure.9 These results came from a large sample size of 3850 patients which is
a strength of this study; however, few studies examining RAI in this setting are available for comparison,
thus limiting this study. Nonetheless, given the excellent prognosis of thyroid cancer and long-life
expectancy in general, it is essential that clinicians and patients understand the risks of developing
secondary cancers from RAI therapy when evaluating treatment options.
Despite the alternative management options and despite studies revealing negative effects as
described above, total thyroidectomy with radioactive iodine remnant ablation is still the number one
treatment option for papillary thyroid cancer.10 The goal of papillary thyroid cancer treatment as defined
by the American Thyroid Association is to eradicate any signs of disease. Disease-free is defined by
negative tumor markers and a negative whole-body scan after treatment which is only achieved by
thyroidectomy, radioactive iodine ablation with iodine-131, and lifelong TSH suppression with
levothyroxine treatment.11 With this combination of treatments, the rate of recurrence is lower when
compared to more conservative management options. A retrospective observational study of over
50,000 patients supported this treatment because it showed that less aggressive surgery, like a
lobectomy, resulted in a higher rate of cancer recurrence and death compared to total thyroidectomy.12
The data for this study were taken from databases and cancer registries which limited the amount of
information that could be studied about each individual patient case but did provide a very large sample
size. Another study published in 2019 focusing on surgical options for papillary thyroid (removing only
the tumor and its margins) reduced surgical risks; however, 5% of these patients had recurrent disease
and required further thyroid surgery.13 This study had a small sample size of only 79 patients and a
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limited follow up period but is one of the only studies that showed clinical outcomes of conservative
thyroidectomy compared to total thyroidectomy for papillary thyroid cancer.
Although total thyroidectomy has several disadvantages, it not only permits, but is required
before remnant ablation with RAI. This option allows for accurate evaluation of recurrence with
thyroglobulin tumor markers which is more useful after the thyroid tissue has been removed.14 Reasons
for resistance to adoption of observation over the traditional treatment pathway have also been
described in another study and included patient fear of a cancer diagnosis, clinician unwillingness to
discuss more conservative options, and lack of observational studies showing the efficacy of different
surgical options.14
With the various options available for treatment of papillary thyroid cancer and the controversy
surrounding them, it appears the best way to manage treatment is to focus on the features of papillary
thyroid cancer that determine its aggressiveness and likelihood of metastases. Despite its excellent
prognosis, significant morbidities are associated with papillary thyroid cancer that can be detrimental if
left untreated and must be evaluated prior to choosing a treatment path. The first and most wellstudied feature of papillary thyroid cancer that increases its mortality rate and risk of recurrence is
tumor size.15 A threshold of 1 cm has consistently been referenced as a determining factor in in choosing
the next steps in therapy; however, a study published in 2014 with a large sample size of 60,000 patients
showed no survival benefit with lobectomy versus thyroidectomy for tumor sizes between 1-4 cm.16
These data were also collected from databases which have similar limitations as noted above regarding
potential for missing information on individual patients and for coding errors (which were less likely).
Alternatively, a study published in 2018 showed that in cases that were initially considered low risk
based on tumor size of < 1cm, 18% of these “low-risk” cases were required to have total thyroidectomy
after initial conservative management (including observation or minimal excision with lobectomy) based
on recurrence or presence of non-low risk lymph node metastases found during surgery.15 An important
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limitation of this study was that the patient population was entirely of Asian ethnicity, individuals who
are known to have the highest percentage of lymph node metastasis. The study design was strong
because it was conducted at a single institution, allowing for consistency in analysis. The evidence from
this study challenges the current recommendations of size being the decision-making factor for surgical
management. Furthermore, it questions which factors, if any, are reliable for deciding optimal
management of this cancer.
The answer to the question of whether observation or surgery with RAI is better may include
assessing the patient for clinical symptoms and signs of extrathyroidal or lymph node involvement.
Presence of factors concerning for lymph node involvement or extrathyroidal extension provide strong
indication for radioactive remnant iodine ablation which requires total thyroidectomy to complete. The
issue with this approach is that lymph node metastases are not always readily apparent on ultrasound
and are often not discovered until the patient is already in surgery. Lymph node metastases is
determined by sampling lymph nodes after dissection for presence of cancer cells. At this point, the
patient has already been exposed to the risks of surgery and observation is no longer an option. The
above argument also applies to multifocal disease, defined as tumors located in both lobes or more than
one tumor present in the same lobe.16 For those individuals, total thyroidectomy is the most efficient
and practical option.
Another factor that can help predict optimal treatment is patient age. Compared to adults,
pediatric papillary thyroid cancer presents differently. Ninety percent of pediatric patients have lymph
node metastases at initial diagnosis.17 In addition, higher rates of cervical lymph node metastases, extrathyroidal extension, and distant metastases are found on initial evaluation. Paradoxically, pediatric
patients also have a better prognosis than adults, possibly due to their improved immune systems and
biologic environments. These findings challenge the traditional treatment approach. However, in a study
in 2004 from the Journal of Pediatric Surgery, 33% of pediatric patients who had conservative treatment
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with hemi-thyroidectomy had tumor recurrence that required a completion thyroidectomy. In pediatric
patients, the high disease recurrence rate and consequent need for surgery completion resulted in
reverting to the standard of treatment of total thyroidectomy, RAI, and levothyroxine
supplementation17. The study has a small sample size of only 56 patients. Nonetheless, individual patient
factors including history of prior radiation and genetic testing results, were available due to the small
sample provided, adding to the study’s strength.
Lastly, the location of the thyroid tumor is important to consider when determining the risk of
papillary thyroid cancer progression. Tumors that are located near the trachea or near the recurrent
laryngeal nerve are considered higher risk given their predisposition to invade these important
structures. In these cases, surgical treatment is recommended.5

Conclusion
With the options available to providers and patients for treatment of papillary thyroid cancer, it
is important to develop guidelines that help providers and patients make well-informed and prudent
decisions. The evidence available on this topic helps provide clarity to patients and clinicians when
making this treatment decision. Based on the risks and benefits of observation versus surgery, and on
the data about features of papillary thyroid cancer that predict its behavior, a relatively non-biased
approach to selecting treatment can be made. According to current evidence, some of the disease
features that qualify for the standard treatment pathway automatically include tumors > 4 cm, multifocal tumors in one or both lobes, pre-operative evidence on ultrasound imaging of tumors extending
outside of the thyroid, lymph node metastases, or distant metastases.14 In addition, patient age appears
to play a major role in disease progression making surgery the preferred treatment option for patients
under the age of 16. Outside of these definitive factors, an informed decision should be made based on
the features of the tumors themselves. Tumors between 1 – 4 cm should be evaluated for other
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aggressive features as listed above (location, metastases) and surgery is likely the best option here as
well; however, patients should be educated that these tumors are typically slow-growing and active
surveillance for up to 5 years can be considered prior to opting for immediate surgery.
Contrary to the guidelines from the ATA, evidence suggests that tumors < 1 cm should be
evaluated for lymph node metastases as they have been found to have a higher than expected
percentage of lymph node invasion. More research is needed to determine lymph node metastases preoperatively which may include assessment of thyroglobulin levels, more advanced imaging techniques,
or fine needle aspiration sampling. If no evidence of lymph node or extra thyroidal metastases is found,
then observation of these tumors should be considered first-line for all patients with tumors < 1cm with
ultrasound follow up every six months to monitor for changing features of the disease.
Although studies on papillary thyroid cancer have traditionally been scarce, the changing
landscape and increasing incidence will likely encourage more research in the coming years that could
help refine optimal treatment guidelines. For example, promising research is on the horizon that uses
molecular markers from the fine needle biopsy aspiration used for diagnosis to determine high versus
low risk phenotypes to further guide treatment18.
Given the rapidly increased incidence of this disease, it is extremely likely that clinicians will be
faced with individuals affected by this disease at some point in their careers. Thus, it is imperative that
clinicians are aware of the new literature on this topic and consult peer-reviewed research studies when
determining treatment plans for their patients with papillary thyroid cancer. If more clinicians and
patients are educated on observation of papillary thyroid cancer as a legitimate treatment option,
surgery can be avoided in many cases, ultimately leading to eliminating risks associated with surgery and
radioactive iodine treatment. Alternatively, knowing what features lead to more aggressive cancers can
help providers make a quick decision for surgery which will avoid any delays in treatment and ideally,
provide better outcomes for patients.
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